Cardiac disease in pregnancy and hypertrophic cardiomyopathy: Difference between revisions

	Cardiac disease in pregnancy Microchapters
Home
Overview
Pathophysiology
Epidemiology and Demographics
Risk Factors
Diagnosis
History and Symptoms
Physical Examination
Electrocardiogram
Exercise Testing
Radiation Exposure
Chest X Ray
Echocardiography
MRI
CT
Catheterization: Pulmonary artery catheterization Cardiac catheterization Cardiac Ablation
Treatment
Cardiovascular Drugs in Pregnancy
Labor and delivery
Resuscitation in Late Pregnancy
Contraindications to pregnancy
Special Scenarios: I. Pre-existing Cardiac Disease: Congenital Heart Disease Repaired Congenital Heart Disease Pulmonary Hypertension Rheumatic Heart Disease Connective Tissue Disorders II. Valvular Heart Disease: Mitral Stenosis Mitral Regurgitation Aortic Insufficiency Aortic Stenosis Mechanical Prosthetic Valves Tissue Prosthetic Valves III. Cardiomyopathy: Dilated Cardiomyopathy Hypertrophic Cardiomyopathy Peripartum Cardiomyopathy IV. Cardiac diseases that may develop During Pregnancy: Arrhythmias Acute Myocardial Infarction Hypertension
Cardiac disease in pregnancy and hypertrophic cardiomyopathy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiac disease in pregnancy and hypertrophic cardiomyopathy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac disease in pregnancy and hypertrophic cardiomyopathy
CDC on Cardiac disease in pregnancy and hypertrophic cardiomyopathy
Cardiac disease in pregnancy and hypertrophic cardiomyopathy in the news
Blogs on Cardiac disease in pregnancy and hypertrophic cardiomyopathy
Directions to Hospitals Treating Cardiac disease in pregnancy
Risk calculators and risk factors for Cardiac disease in pregnancy and hypertrophic cardiomyopathy

VisualWikitext

Latest revision as of 20:48, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Anjan K. Chakrabarti, M.D. [2]

Overview

Patients with pre-existing cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during pregnancy, labor, and delivery. In addition to these patients, there is a subset of patients who will develop peripartum cardiomyopathy.

Pathophysiology

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease due to mutations of the cardiac sarcomere proteins, which result in asymmetric hypertrophy of the left ventricle, a nondilated left ventricular cavity, and preserved systolic function with impaired diastolic function.^[1]

Left ventricular outflow tract obstruction (LVOT) is present at rest in approximately 20% of patients.^[2]

Natural History, Complications and Prognosis

Although most women with HCM with minimal or mild symptoms tolerate pregnancy well, the risks associated with pregnancy include:^[3]

Sudden death, particularly in patients with severe outflow obstruction or other risk factors for sudden cardiac death.
Hemodynamic deterioration, particularly in those with moderate or severe symptoms before pregnancy.

Treatment

Medical Therapy

Management considerations during pregnancy, labor, and delivery include:^[3]

Beta-blockers and calcium channel blockers are safe in this population.
Avoid decreases in preload (straining, dehydration, etc.).
Avoid inotropes and vasodilators.
Tachycardia and reduced preload from valsalva can both adversely affect the HCM patient, so labor should be in a high-risk center.
Epidural anesthesia should be avoided due to the potential for hypotension.
Prostaglandins for the induction of labor is not advised, secondary to inherent vasodilatory effects.
General anesthesia is often employed, and vasopressors and fluids can be given to treat hypotension.

Related Chapter

This section will primarily focus on hypertrophic cardiomyopathy (HCM) in pregnancy. For a more detailed discussion of hypertrophic cardiomyopathy, click here.

References

↑ Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P; et al. (2002). "Risk associated with pregnancy in hypertrophic cardiomyopathy". J Am Coll Cardiol. 40 (10): 1864–9. PMID 12446072.
↑ Spirito P, Autore C (2006). "Management of hypertrophic cardiomyopathy". BMJ. 332 (7552): 1251–5. doi:10.1136/bmj.332.7552.1251. PMC 1471918. PMID 16735335.CS1 maint: PMC format (link)
↑ ^3.0 ^3.1 Stergiopoulos K, Shiang E, Bench T (2011). "Pregnancy in patients with pre-existing cardiomyopathies". J Am Coll Cardiol. 58 (4): 337–50. doi:10.1016/j.jacc.2011.04.014. PMID 21757110.

Template:WH Template:WS CME Category::Cardiology

[pmid12446072-1] Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P; et al. (2002). "Risk associated with pregnancy in hypertrophic cardiomyopathy". J Am Coll Cardiol. 40 (10): 1864–9. PMID 12446072.

[pmid16735335-2] Spirito P, Autore C (2006). "Management of hypertrophic cardiomyopathy". BMJ. 332 (7552): 1251–5. doi:10.1136/bmj.332.7552.1251. PMC 1471918. PMID 16735335.CS1 maint: PMC format (link)

[pmid21757110-3] 3.0 ^3.1 Stergiopoulos K, Shiang E, Bench T (2011). "Pregnancy in patients with pre-existing cardiomyopathies". J Am Coll Cardiol. 58 (4): 337–50. doi:10.1016/j.jacc.2011.04.014. PMID 21757110.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-{{Pregnancy and heart disease}}
+__NOTOC__
+{{Cardiac disease in pregnancy }}
-{{CMG}}; '''Associate Editor-In-Chief:'''  {{AC}}
+{{CMG}}; {{AOEIC}} {{AC}}
 ==Overview==
+Patients with pre-existing [[Cardiomyopathy|cardiomyopathies]] such as [[dilated cardiomyopathy]] and [[HOCM|hypertrophic cardiomyopathy]], often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during [[pregnancy]], [[labor]], and [[delivery]].  In addition to these patients, there is a subset of patients who will develop [[Peripartum cardiomyopathy|peripartum cardiomyopathy]].
+==Pathophysiology==
+[[Hypertrophic cardiomyopathy]] ([[HCM]]) is an autosomal dominant disease due to mutations of the cardiac sarcomere proteins, which result in asymmetric hypertrophy of the left ventricle, a nondilated left ventricular cavity, and preserved [[systolic function]] with impaired [[diastolic function]].<ref name="pmid12446072">{{cite journal| author=Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P et al.| title=Risk associated with pregnancy in hypertrophic cardiomyopathy. | journal=J Am Coll Cardiol | year= 2002 | volume= 40 | issue= 10 | pages= 1864-9 | pmid=12446072 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12446072  }} </ref>
-Patients with pre-existing [[Cardiomyopathy|cardiomyopathies]] prior to pregnancy often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during pregnancy, labor, and delivery.  In addition to these patients, there is a subset of patients who will develop [[Peripartum cardiomyopathy|peripartum cardiomyopathy]].
+[[Left ventricular outflow tract obstruction]] ([[LVOT]]) is present at rest in approximately 20% of patients.<ref name="pmid16735335">{{cite journal| author=Spirito P, Autore C| title=Management of hypertrophic cardiomyopathy. | journal=BMJ | year= 2006 | volume= 332 | issue= 7552 | pages= 1251-5 | pmid=16735335 | doi=10.1136/bmj.332.7552.1251 | pmc=PMC1471918 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735335  }} </ref>
-==Pre-Existing Cardiomyopathies==
+==Natural History, Complications and Prognosis==
+Although most women with [[HCM]] with minimal or mild symptoms tolerate pregnancy well, the risks associated with pregnancy include:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
-===[[Dilated Cardiomyopathy|Dilated Cardiomyopaty]]===
+*[[Sudden death]], particularly in patients with severe outflow obstruction or other risk factors for [[sudden cardiac death]].
+*Hemodynamic deterioration, particularly in those with moderate or severe symptoms before pregnancy.
-This section will primarily focus on dilated cardiomyopathy (DCM) in pregnancy.  For a more detailed discussion of dilated cardiomyopathy, click [[Dilated Cardiomyopathy|here]].
-Currently, DCM is responsible for "approximately 10,000 deaths and 46,000 hospital stays each year in the United States and is the most common indication for cardiac transplantation."<ref name="pmid1590237">{{cite journal| author=Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV et al.| title=Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. | journal=Am J Cardiol | year= 1992 | volume= 69 | issue= 17 | pages= 1458-66 | pmid=1590237 | doi= | pmc= | url= }} </ref>  The cause often remains unknown, in up to 50% of cases.<ref name="pmid10760308">{{cite journal| author=Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al.| title=Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. | journal=N Engl J Med | year= 2000 | volume= 342 | issue= 15 | pages= 1077-84 | pmid=10760308 | doi=10.1056/NEJM200004133421502 | pmc= | url= }} </ref>
-In general, women with dilated cardiomyopathy are advised to avoid pregnancy for the following reasons:
-*Dilated cardiomyopathy has been associated with A-type lamin gene defects, which are associated with a high rate of heart failure and life-threatening arrhythmias, as predicted by NYHA functional class<ref name="pmid18926329">{{cite journal| author=Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A et al.| title=Long-term outcome and risk stratification in dilated cardiolaminopathies. | journal=J Am Coll Cardiol | year= 2008 | volume= 52 | issue= 15 | pages= 1250-60 | pmid=18926329 | doi=10.1016/j.jacc.2008.06.044 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18926329  }} </ref>
-*The increase in intravascular volume and cardiac output during pregnancy leads to a greater risk for complications in women with dilated cardiomyopathy, especially in the 3rd trimester
-*A history of cardiac events including previous episodes of heart failure, atrial fibrillation or atrial flutter, transient ischemic attack, or a history of cardiac events before pregnancy is predictive of negative pregnancy-related cardiac outcomes<ref name="pmid11994252">{{cite journal| author=Siu SC, Colman JM, Sorensen S, Smallhorn JF, Farine D, Amankwah KS et al.| title=Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. | journal=Circulation | year= 2002 | volume= 105 | issue= 18 | pages= 2179-84 | pmid=11994252 | doi= | pmc= | url= }} </ref>
-The following should be considered when managing heart failure during pregnancy:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
-*Goals are similar to non-pregnant patients, including continuation of chronic therapies (with a few exceptions, including ACE Inhibitors, Angiotensin Receptor Blockers, and Aldosterone antagonists)
-*Beta-blockers can and should be continued through pregnancy
-*Vasodilator therapy can be achieved with Amlodipine and Hydralazine safely
-*Sodium restriction and digoxin can both be used during pregnancy
-*In the setting of acute decompansation, intravenous diuretics, vasodilators, and monitoring with right heart cathterization are all acceptable
-Finally, the following should be considered during labor and delivery:
+==Treatment==
+===Medical Therapy===
+Management considerations during pregnancy, labor, and delivery include:<ref name="pmid21757110">{{cite journal| author=Stergiopoulos K, Shiang E, Bench T| title=Pregnancy in patients with pre-existing cardiomyopathies. | journal=J Am Coll Cardiol | year= 2011 | volume= 58 | issue= 4 | pages= 337-50 | pmid=21757110 | doi=10.1016/j.jacc.2011.04.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21757110  }} </ref>
+*[[Beta-blockers]] and [[calcium channel blockers]] are safe in this population.
+*Avoid decreases in [[preload]] (straining, dehydration, etc.).
+*Avoid [[inotropes]] and [[vasodilators]].
+*[[Tachycardia]] and reduced [[preload]] from [[valsalva]] can both adversely affect the [[HCM]] patient, so labor should be in a high-risk center.
+*[[Epidural anesthesia]] should be avoided due to the potential for [[hypotension]].
+*[[Prostaglandins]] for the induction of labor is not advised, secondary to inherent vasodilatory effects.
+*[[General anesthesia]] is often employed, and vasopressors and fluids can be given to treat [[hypotension]].
+==Related Chapter==
+*This section will primarily focus on [[hypertrophic cardiomyopathy]] ([[HCM]]) in pregnancy. For a more detailed discussion of hypertrophic cardiomyopathy, click [[Hypertrophic Cardiomyopathy|here]].
 ==References==
 {{Reflist|2}}
+{{WH}}
+{{WS}}
+[[CME Category::Cardiology]]
+[[Category:Disease]]
 [[Category:Cardiology]]
+[[Category:Emergency medicine]]
 [[Category:Obstetrics]]
-[[Category:Disease]]
-{{WH}}
-{{WS}}